Nilotinib therapy in chronic myelogenous leukemia: The strength of high selectivity on BCR/ABL

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 530-536

  Breccia, Massimi ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB;

ABNORMAL LABORATORY RESULT; ANEMIA; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; GENE MUTATION; GERIATRIC PATIENT; HEADACHE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PROTEIN EXPRESSION; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 68349126965     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488468     Document Type: Review

References (45)

1. Faderl S, Talpaz M, Estrov Z, Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-19.
2. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
3. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4-10.
4. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-8.
5. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-17.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. Cancer J Clin 2006; 20: 106-30.
7. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-30.
8. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53.
9. Druker BJ, Guilhot F, O'Brien S, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
10. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all firstline treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080-85.
11. Hughes TP, Hochhaus A, Branford S, Muller MC, Foroni L, Druker BJ, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 Mo: An analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood 2008; 112: abstr 334.
12. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. European leukemia net evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia. Net Blood 2006; 108: 1809-20.
13. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-29.
14. O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008; 112: abstr 186.
15. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-31.
16. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007; 44: S15-S24.
17. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007; 249: 121-32.
18. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. International Randomized Study of Interferon vs STI571 (IRIS) Investigators efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009; 115: 551-60.
19. Marin D, Goldman JM, Olavarri, E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003; 102: 2702-3.
20. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003; 9: 2092-7.
21. Jabbour E, Kantarjian H, Jones D, Shan J, O'Brien SG, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009; 113: 2154-60.
22. Manley PW, Bretenstein W, Bruggen J, Cowan-Jacob SW, Furet P, Mestan J, Meyer T. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg Med Chem Lett 2004; 14: 5793-7.
23. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754: 3-13.
24. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-64.
25. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature1994; 372: 746-54.
26. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-41.
27. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941-7.
28. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-5.
29. Hochhaus A, Kim DW, Martinelli G, Hughes TP, Soverini S, Branford S, et al. Nilotinib efficacy according to baseline BCR-ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP). Blood 2008; 112: 3216.
30. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332-8.
31. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5.
32. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online 2003; 5: 204-10.
33. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64(18): 6385-9.
34. Kantarjian H, Giles F, Wunderle L, Balla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive all. New Engl J Med 2006; 354: 2542-51.
35. Kantarjian H, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112: 3238.
36. Mahon FX, Hayette S, Lagarde V, Nicolini FE, Belloc F, Leroy C, et al. Lyn kinase overexpression is one of the mechanisms of resistance to nilotinib in chronic myeloid leukemia. Blood 2008; 112: 3181.
37. Lipton JH, le Coutre PD, Wang J, Yang M, Szczudlo T, Giles F. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood 2008; 112: 3233.
38. Nicolini F, Alimena G, Shen Z, Al-Ali HK, Turbina A, Smith G, et al. Expanding nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML): updated safety analysis. Haematologica 2008; 2: 134.
39. le Coutre PD, Giles F, Hochhaus A, Apperley JF, Ossenkoppele G, Haque A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112: 3229.
40. Jabbour E, Kantarjian HM, Baccarani M, le Coutre PD, Haque A, Gallagher NJ, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CMLAP). Blood 2008; 112: 3215.
41. Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G, et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2008; 112: 446.
42. Rosti G, Castagnetti F, Poerio A, Breccia M, Levato L, Capucci A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 Mg daily as first line treatment of ph-positive chronic myeloid leukemia in chronic phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood 2008; 112: 181.
43. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007; 109: 2112-20.
44. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007; 109: 3609-10.
45. Giles FJ, Larson RA, Kantarjian HM, le Coutre P, Baccarani M, Haque A, et al. nilotinib in patients (pts) with philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 2007; 110: 25.